ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022
Reducing onchocerciasis-associated morbidity in onchocerciasis-endemic foci with high ongoing transmission: a focus on the children.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- HISTONCHO: A dataset of intervention histories for onchocerciasis control & elimination in sub-Saharan Africa.Scientific data · 2026Article
- Onchocerciasis and non-communicable diseases in the Bafut Health District, Cameroon: Knowledge, attitudes, and practices towards community-directed treatment with ivermectin.PLoS neglected tropical diseases · 2026Article
- The Nodding syndrome cerebrospinal fluid proteome: a lens into neurodevelopmental failure consistent with environmentally triggeredFrontiers in molecular neuroscience · 2026Article
- Reaching elimination of onchocerciasis transmission with long-term vector control and ivermectin treatment in Togo.Nature communications · 2025Article
- Community-directed treatment with ivermectin in Maridi, South Sudan: Impact of an onchocerciasis awareness campaign and bi-annual treatment on therapeutic coverage.PLoS neglected tropical diseases · 2025Article
- Accelerating onchocerciasis elimination in humanitarian settings: lessons from South Sudan.International health · 2025Article
- Epidemiology of epilepsy in Wulu County, an onchocerciasis-endemic area in South Sudan.Heliyon · 2024Article
- Modelling onchocerciasis-associated epilepsy and the impact of ivermectin treatment on its prevalence and incidence.Nature communications · 2024Article
- A 14-year review (2007-2020) of helminthiasis epidemiology in a hospital in Southern Madrid, Spain.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Review
- Sociodemographics, Clinical Factors, and Biological Factors Associated with Loiasis in Endemic Onchocerciasis Areas in Southern Gabon.The American journal of tropical medicine and hygiene · 2023Article
- Epilepsy and nodding syndrome in association with an Onchocerca volvulus infection drive distinct immune profile patterns.PLoS neglected tropical diseases · 2023Article
- Status of epilepsy in the tropics: An overlooked perspective.Epilepsia open · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
Abstract
Efforts are being directed toward the elimination of onchocerciasis transmission in endemic areas with community-directed treatment with ivermectin (CDTI) in Africa, which greatly reduces onchocerciasis-associated disease. However, onchocerciasis remains a major public health problem in areas of South Sudan, the Democratic Republic of the Congo, Cameroon, and the Central African Republic. Strengthening onchocerciasis elimination efforts in areas with a high prevalence of disease burden is crucial to decrease transmission, morbidity, and mortality. We argue that clinical trials are needed to investigate the safety and efficacy of ivermectin treatment of Onchocerca volvulus-infected pregnant women and children younger than 5 years. Crucially, 6-monthly administration of ivermectin in school-age children at risk of onchocerciasis-associated epilepsy could be achieved by supplementing annual CDTI with an extra round of ivermectin treatment during Child Health Days in schools and/or other distribution sites every year. These strategies would help achieve the elimination of onchocerciasis and its associated disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.